Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

An international Delphi panel convened by the World Allergy Organization (WAO) ACT-UP! initiative reached consensus on 33 of 35 statements addressing 

, recommending action levels for "may contain" warnings rely on population-adjusted eliciting dose (ED

) reference doses rather than fixed allergen concentrations.¹ ED

 denotes the amount of allergen estimated to trigger an objective reaction in no more than 5% of the allergic population.

Precautionary allergen labeling remains unregulated and voluntary in most countries, a gap the WAO first flagged more than a decade ago, and food businesses have responded with defensive over-labelling even when unintended allergen presence is unlikely.¹ The FAO/WHO Expert Consultation, convened through the Codex Committee on Food Labelling, previously proposed reference-dose thresholds for priority allergens:

2 mg total protein: peanut, egg, milk, sesame

However, reference-dose thresholds offer limited opportunity for clinician input. The ACT-UP! working group launched this 3-round e-Delphi involving 35 experts across 21 countries to fill the resulting gap.

"[Precautionary allergen labelling] should only be applied when a legally regulated risk assessment indicates the likelihood of unintended allergen presence, which can pose a risk to allergic individuals," wrote author Antonio Bognanni, MD, PhD, from McMaster University, and colleagues.¹

A 35-member international Delphi panel convened by the WAO ACT-UP! initiative reached consensus on 33 of 35 statements on precautionary allergen labeling practice across 3 rounds.

Action levels should rely on reference doses, specifically ED

 values, rather than fixed ppm concentrations.

“May contain X" emerged as the preferred wording.

No consensus emerged on how to communicate residual risk to allergic consumers below the ED

threshold, despite 70% agreement on the need for such communication.

Delphi Methodology and Consensus on Reference-Dose Thresholds

The panel, 60% clinicians alongside methodologists, food technologists, regulators, dietitians, and patient advocates, rated 35 statements across 7 domains on a 5-point Likert scale over 3 rounds, with a 100% response rate at every round. Consensus was predefined as ≥ 70% agreement or disagreement, excluding neutral responses, with stability requiring < 10% variation in mean scores between rounds. Statements reaching ≥ 90% agreement with no change in status across 2 rounds were dropped from further voting to limit survey fatigue.

Consensus climbed from 86.1% of statements (31 of 35) in round 1 to 91.4% (32 of 35) and 94.3% (33 of 35) in rounds 2 and 3, respectively. The panel agreed precautionary allergen labeling should apply only when unintended allergen presence exceeds an action level set through a mandatory, preferably quantitative, risk assessment. Action levels should be based on reference doses of total allergenic protein for a typical portion, rather than a fixed concentration such as 10 ppm, and specifically on ED

 values rather than the more conservative ED01.This would protect against the risk of precautionary allergen labeling overuse.

Communication, Free-From Labels, and Liability Findings

Fixed-concentration thresholds drew the most disagreement: panelists rejected a 5 ppm cutoff, while 10 ppm never reached consensus. On wording, "may contain X" was the consistently preferred phrasing, rising from 52% support in round 1 to 71% by round 3, ahead of "may contain traces of X" and "not suitable for people with an allergy to X."

Precautionary allergen labelling communication posted the lowest final domain consensus: 70% of the panel agreed consumers need information about residual risk from unintended allergen presence below the reference dose, but a proposed 2-tier precautionary allergen labelling system failed to reach consensus across rounds.

On free-from claims, 97% of panelists agreed labels declaring an allergen absent should mean no detectable presence, including via unintended allergen presence. A consensus reached 81% for excluding precautionary allergen labeling on vegan-labeled foods for milk, egg, or other animal-derived allergens, and 80% favored redefining "gluten-free" to mean an absence of gluten rather than the current 20-ppm threshold. The liability domain reached full consensus: food business operators demonstrating regulatory compliance should not be held liable for reactions caused by unintended allergen presence.¹

The recommendations are intended to reinforce the FAO/WHO Expert Consultation, currently under review by the Codex Committee on Food Labelling, by providing clinician- and interest-holder-derived input largely absent from the regulatory process to date.¹ The authors identify harmonized international food-consumption datasets, multilingual validation of precautionary allergen labelling wording, and continued monitoring of allergic reactions occurring below current reference-dose thresholds as future research priorities.

Bognanni A, Sousa-Pinto B, Morais-Almeida M, et al. World Allergy Organization (WAO) Consensus on the use and practice of precautionary allergen labelling: The international ACT-UP! e-Delphi. 

Turner PJ, Bognanni A, Arasi S, et al. Time to ACT-UP: update on precautionary allergen labelling (PAL). 

Articles

A 35-expert, 21-country WAO ACT‑UP! e‑Delphi achieved consensus on 33/35 statements to standardize precautionary allergen labeling (PAL) and reduce defensive overuse. PAL should be applied only when a mandatory, preferably quantitative, risk assessment shows unintended allergen presence exceeds an action level. Action levels should be portion-based and anchored to population-adjusted ED05 reference doses of total allergenic protein, not fixed ppm thresholds. “May contain X” emerged as preferred wording. Strong agreement supported stringent “free‑from” meanings and liability protection when operators comply with regulations.

An international 35-expert Delphi panel reached consensus on 33 of 35 statements on precautionary allergen labelling reference doses.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

WAO Delphi Consensus Endorses ED05-Based Allergen Labelling

Thomas Pieber, MD, is the chair of the Division of Endocrinology and Diabetology at the Department of Internal Medicine at the Medical University of Graz.

Investigational Rapid-Acting U500 Insulin Maintains Efficacy Regardless of BMI

AT278, an investigational U500 rapid-acting insulin aspart formulation in development by Arecor Therapeutics, has demonstrated greater glucose reduction and rapid onset regardless of body mass index (BMI) among patients with 

 often exhibit severe insulin resistance, drastically increasing their daily requirements. Concentrated insulins have become the cornerstone of treatment for these patients – however, the only approved high-concentration U500 option, HumIns-U500, significantly alters the pharmacokinetic profile of regular insulin and prevents it from meeting physiological meal-related needs. AT278-U500 is currently in development to address this gap.

“We have tested the compound before in 

, and it turned out to be one of the fastest insulins we have ever had in our hands,” Thomas Pieber, MD, chair of the Division of Endocrinology and Diabetology at the Department of Internal Medicine at the Medical University of Graz, told 

 in an exclusive interview. “We asked the question, is it also that fast in type 2? It is. We asked the question, is it also fast when you look at different BMIs, normal and very high BMI? And indeed, it maintains its fast action.”

Pieber and colleagues conducted a phase 1, single-dose, randomized, double-blind, 2-way crossover glucose clamp study, including an extension period for an open-label third comparator. Patients were eligible for inclusion if they were aged 18-75 years and had T2D for ≥6 months. Additionally, patients were required to have a BMI of 25-45 kg/m

 and an HbA1c ≤80 mmol/mol (≤9.5%). Patients with known or suspected hypersensitivity to the study medications or clinically significant concomitant diseases were excluded, among other criteria.

After initial screening, patients would attend ≤3 clamp visits, each separated by a 5-21-day washout period. Patients were given a single subcutaneous dose of 0.5 U/kg of AT278-U500 or InsAsp-U100 in randomized sequence at the first 2 clamp visits. At the third visit, patients were given HumIns-U500 instead. At each visit, patients consumed a standardized meal, began fasting at 10:00 PM, and were initiated into the euglycemic glucose clamp at 11:00 PM with an overnight run-in period.

The study’s primary endpoint was area under the glucose infusion rate (GIR)-time curve from 0 to 60 minutes. Endpoints were analyzed via a linear mixed model, with treatment, treatment sequence, and visit as fixed effects and participant as random effect. A sensitivity analysis was conducted as well, including solely patients who completed euglycemic clamps with AT278-U500 and InsAsp-U100.

A total of 69 patients were screened, of whom 41 were admitted and randomized into the trial. Of these patients, 2 withdrew after the first clamp visit due to adverse events unrelated to treatment. 39 patients completed both euglycemic clamps with AT278-U500 and InsAsp-U100, while 36 completed the additional open label comparison with HumIns-U500.

Over the course of the study, AT278-U500 displayed a substantially faster insulin absorption than InsAsp-U100 and HumIns-U500 (

: 9 min vs. 35 min vs. 55 min), which lead to a substantially higher glucose-lowering effect within the first hour than both InsAsp-U100 (treatment ratio, 2.02; 95% CI, 1.64-2.5) and HumIns-U500 (treatment ratio, 3.91; 95% CI, 1.89-5.27).

When divided by median BMI, Pieber and colleagues found that the AUC was substantially higher with AT278-U500 in both the low- and high-BMI subgroup compared to InsAsp-U100. Linear regression indicated a significant inverse relationship between AUC and BMI for InsAsp-U100, while AT278-U500 had no similar relationship. Overall insulin exposure was also similar for AT278-U500 and InsAsp-U100, while overall glucose lowering was comparable across all treatments.

Ultimately, Pieber and colleagues concluded that AT278-U500 maintains its ultra-rapid onset characteristics regardless of a patient’s BMI. This represents the first-ever ultra-rapid U500 option for prandial dosing in patients with T2D who are insulin-resistant. However, the team also noted the lack of faster-acting insulin analogues currently in use in clinical practice, such as faster aspart U100, URLi U100 and U200. The team acknowledges that head-to-head comparison studies with these formulations would provide important data regarding AT278-U500’s relative performance.

“One of our next steps will be comparing faster insulins against this new U500 insulin,” Pieber said. “It was simply a technical limitation why we haven’t tested it. It somewhat limits the clinical conclusions we can draw. That’s another study that can be done in the near future.”

Editors’ Note: Pieber reports disclosures with Adocia, Arecor, AstraZeneca, Eli Lilly, Novo Nordisk, Sanofi, and others.

Svehlikova E, Gatschelhofer C, Lackner B, et al. A new highly concentrated insulin aspart AT278 (500 u/mL) demonstrates Ultra‐rapid pharmacokinetic and pharmacodynamic properties in type 2 diabetes regardless of BMI. Diabetes, Obesity and Metabolism. Published online July 30, 2026. 

Eli Lilly and Company, “HUMULIN R U-500 (Insulin Human) Injection, for Subcutaneous Use [Prescribing Information],” Accessed August 17, 2026, 

https://pi.lilly.com/us/humulin-r-u500-pi.pdf

Videos

Thomas Pieber, MD, discusses a recent phase 1 trial investigating AT278’s efficacy in patients with T2D and obesity compared to other fast-acting insulins.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Type 2 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Jessica Mercer, MD, serves as co-managing owner of Georgia Dermatology Partners near Atlanta, Georgia.

Skin of Color Savvy: The Art and Science of Treating Patients of Color

Alexis said mentorship provides guidance and inspiration that shapes most physicians' career paths, often sparking interest in specific dermatology subspecialties.

Both physicians recommended mentees engage beyond scheduled clinical hours, noting that informal time after patients leave often yields the most valuable learning.

Alexis said mentorship can directly improve care for patients with skin of color by supplementing inconsistent training exposure with real-world clinical experience.

Andrew Alexis, MD, MPH, professor of clinical 

 at Weill Cornell Medicine in New York City, joined host Jessica Mercer, MD, co-managing owner of Georgia Dermatology Partners near Atlanta, Georgia, on 

, to discuss how mentorship shapes careers and improves care for patients with skin of color.

 leaders. Alexis, who has mentored Mercer since early in her career, said mentorship offers guidance, support, and inspiration most physicians rely on. He explained that observing a mentor's clinical approach can spark interest in specific areas of dermatology, pointing to Mercer's path toward hair and pigmentary disorders as an example of how early exposure through mentorship can shape a lasting career focus.

Skin of Color Savvy: Mentorship in Dermatology—Building the Next Generation of Leaders

Andrew Alexis, MD, MPH, professor of clinical dermatology at Weill Cornell Medicine in New York City, joined host Jessica Mercer, MD, co-managing owner of Georgia Dermatology Partners near Atlanta, Georgia, on Skin of Color Savvy: The Art and Science of Treating Patients of Color, to discuss how mentorship shapes careers and improves care for patients with skin of color.

Alexis, who has mentored Mercer since early in her career, said mentorship offers guidance, support, and inspiration most physicians rely on. He explained that observing a mentor's clinical approach can spark interest in specific areas of dermatology, pointing to Mercer's path toward hair and pigmentary disorders as an example of how early exposure through mentorship can shape a lasting career focus.

How Should Mentees Approach the Mentor-Mentee Relationship?

Alexis advised mentees to fully immerse themselves in the experience rather than limiting engagement to scheduled clinical hours. He said valuable learning often occurs during informal moments after patients leave for the day, when mentors may be reviewing charts or handling administrative tasks, providing space for relaxed conversation and reflection. Mercer agreed, noting that mentees benefit from establishing clear goals with mentors at the outset of the relationship.

Does Mentorship Improve Outcomes for Patients With Skin of Color?

Alexis said mentorship can directly benefit patients with skin of color, particularly given inconsistent training exposure to conditions such as pigmentary disorders, keloids, and hair and scalp disorders across different programs. He explained that mentorship allows trainees to supplement textbook knowledge with real-world clinical experience, helping close training gaps that persist in the literature on skin of color dermatology.

Mercer reflected on her own path, crediting mentors including David Peng, MD, at the University of Southern California and Charles McDonald, MD, at Brown University for shaping her career, including her decision to pursue dermatopathology. She said she now mentors students and staff in her practice, several of whom have gone on to medical school or physician assistant programs, describing mentorship as a legacy that continues to expand equitable care in dermatology.

To learn more about SOCS’s programs and initiatives, visit 

Editor’s note: This episode was summarized with the help of AI tools. Alexis and Mercer had no relevant disclosures of note.

Perlman KL, Williams NM, Park JH, et al. Skin of color lacks representation in medical student resources: A cross-sectional study. Int J Womens Dermatol. 2021 Jan 8;7(2):195-196. 

Podcasts

Andrew Alexis, MD, MPH, and Jessica Mercer, MD, discuss how mentorship shapes dermatology careers and improves care for skin of color.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Hosted by Skin of Color Society and produced by HCPLive, 

 delves into the latest research, clinical insights, and culturally intelligent care practices in dermatology with leading experts. 

Whether it’s groundbreaking research, practice-changing insights, or highlights from the SOCS community, this twice-monthly program provides dermatologists and care providers with expert perspectives on treating patients with skin of color.

Samir V Parikh, MD, FASN is a clinical professor of medicine in the Division of Nephrology at The Ohio State University Wexner Medical Center in Columbus, OH.

Credit: The Ohio State University Wexner Medical Center

 is increasingly understood as a B-cell–driven disease. Class-switched B cells and the plasma cells they give rise to act as a kind of "B-cell factory," producing galactose-deficient IgA1, which forms circulating immune complexes that deposit in the glomeruli and drive kidney injury. As therapies targeting this pathway move into practice, many nephrologists are applying immunologic mechanisms outside their core training. 

Samir Parikh, MD, of The Ohio State University Wexner Medical Center, discussed why B-cell biology warrants more attention in clinical education, why IgAN still lacks validated biomarkers, how he approaches treatment sequencing in the absence of combination-therapy data, and why earlier detection remains a central unmet need in IgAN care.

Q&A: Understanding the B-Cell Pathway in IgA Nephropathy, With Samir Parikh, MD

HCPLive: IgAN is increasingly understood as an immune-mediated disease involving multiple pathways. Which aspects of the disease biology do you think are most important for clinicians to understand today?

Parikh: I think one of the areas that is probably least well understood is the B-cell pathways that actually lead to the class switching and the production of galactose-deficient IgA1, and the plasma blasts and plasma cells that continue to produce them. Nephrologists by trade are not immunologists, but we are using immunologic drugs, and that pathway seems to be very key in the production of galactose-deficient IgA1 and then getting into circulation in the immune complexes. It's really important that we spend time focusing on educating on the B-cell factory, so to speak, that drives IgA production and the resulting IgA nephropathy.

HCPLive: As our understanding of the molecular drivers of IgAN becomes more refined, do you anticipate a shift toward more personalized treatment?

Parikh: I hope so. Right now, we don't have IgAN-specific biomarkers, and I think one of the hopes for the future—in the next five to ten years—is that we're able to identify specific biologic markers that can help inform disease. We have a lot of tools in the toolkit, but we don't know how to stratify who needs what. Having markers available that can potentially guide treatment decisions and explain the heterogeneity a little bit will be better for patients. That will allow us to say, based on your profile, these therapies will work best for you, and hopefully optimize outcomes—stabilizing or even improving kidney function over time.

With so many new therapeutic modalities emerging, how are you thinking about sequencing treatment for patients?

Parikh: We don't have all the answers to that because we don't have data on combination therapies yet. But we understand the mechanisms of disease, so you use the data available to you—biopsy, proteinuria, hematuria, GFR, patient factors—and ask what therapies would benefit this particular patient most, based on their overall profile. In most cases, that's going to begin with hitting the immunologic drivers of disease. You need to turn off that inflammation, but you also need to do things that are protective to the kidney and help slow the maladaptive changes that are happening. You can think about a profile where you're using endothelin receptor antagonists and RAS blockers to help control things in the kidney, but then also looking proximal to turn off the disease so we can arrest the process driving the damage in the first place. Our thoughts on this are going to evolve as more data come out and we get real-world experience with these combination therapies.

HCPLive: What is one change you hope to see in IgAN care over the next few years?

Parikh: In the short term, the biggest push we have to make is to recognize the disease earlier. We have to get in front of our primary care colleagues, our urologists, OB/GYNs, ER physicians, even our nephrology colleagues, to say hematuria is not benign—especially if it's glomerular hematuria. We need to evaluate that. I would love to see urinalysis become part of routine screening on physical exams. I would love to educate primary care that hypertension is not usually essential or primary, and we have to look for other causes when we see it, especially in younger populations. The workup is not expensive or extraordinary—it's very basic, it's just forgotten. Right now we're seeing patients way too late, coming to clinical attention at chronic kidney disease stage three or four. We want to recognize and see the disease sooner, because a lot of these patients are asymptomatic and may not present until they've accumulated a lot of chronic damage. So that's what I hope to see.

Barratt J, Floege J, Rovin BH, et al. Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney Int. 2025. 

https://www.kidney-international.org/article/S0085-2538(25)00278-9/fulltext

Suzuki H, Kiryluk K, Novak J, et al. IgA Nephropathy: Core Curriculum 2021. Am J Kidney Dis. 2021. 

https://www.ajkd.org/article/S0272-6386(21)00598-9/fulltext

IgA nephropathy pathobiology increasingly centers on a B-cell–driven “factory” of class-switched B cells and plasma cells producing galactose-deficient IgA1, enabling circulating immune complex formation and glomerular deposition. Clinical uptake of immunologic therapies is outpacing many nephrologists’ formal immunology training, heightening the need for targeted education. Personalized care remains constrained by the absence of validated IgAN-specific biomarkers to stratify heterogeneous disease and match patients to emerging modalities. In practice, treatment sequencing relies on clinicopathologic risk features and mechanistic rationale, while earlier recognition via routine urinalysis and hematuria workups is a key unmet need.

Samir Parikh, MD, on the B-cell pathway in IgA nephropathy, biomarker gaps, treatment sequencing, and the case for earlier detection.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Understanding the B-Cell Pathway in IgA Nephropathy, With Samir Parikh, MD

Children with lower household income, lower parental health literacy, and greater neighborhood-level deprivation were significantly less likely to report resolution of 

The factors linked to food allergy resolution in children have remained poorly defined despite rising prevalence and the substantial health, psychosocial, and financial burden the diagnosis places on families. According to Food Allergy, Research & Education (FARE), allergies to milk, egg, wheat, and soy often resolve in childhood, whereas allergies to peanuts, tree nuts, and shellfish are often lifelong.

“Fewer than 20% of children will outgrow their peanut allergy,” said Kirsi Järvinen-Seppo, MD, chief of pediatric allergy and immunology at UR Medicine Golisano Children’s Hospital.

 “That is why peanut remains one of the most researched and carefully managed food allergies in pediatrics.”

Which food allergies are most likely to resolve in children?

In the FORWARD cohort, milk (35%), soy (32%), and wheat (27%) allergies were resolved most often, while peanut (3.8%) and shellfish (3.5%) allergies rarely resolved.

Do racial disparities affect food allergy resolution?

Yes. White children reported resolution of food allergy more frequently than Black and Hispanic children across all common allergens, even after adjustment for socioeconomic covariates.

What social factors predict whether a child outgrows a food allergy?

Lower household income, lower parental health literacy scores, and higher area deprivation index were each associated with a lower likelihood of resolution across the 9 food allergens assessed.

The team, led by Mahboobeh Mahdavinia, MD, PhD, from McGovern Medical School at UT Health Houston, drew on caregiver surveys and electronic health record data from FORWARD (Food Allergy Outcomes Related to White and African American Racial Differences), a multicenter observational study, to identify demographic and clinical factors associated with resolution among children with ≥ 1 active food allergy.¹ Participants were allergic to either milk, soy, wheat, peanut, or shellfish.

Food Allergy Resolution Rates in the FORWARD Cohort

The analysis included 1359 participants younger than 12 years with physician-diagnosed IgE-mediated food allergy enrolled in FORWARD. Investigators compared demographic and clinical characteristics between children with and without caregiver-reported resolution of ≥ 1 food allergy at enrollment, then built multivariable logistic regression models evaluating associations between resolution and race/ethnicity, household income, health literacy scores, and area deprivation index (ADI).¹

Resolution rates varied widely by allergen. Milk allergy resolved most often (35%), followed by soy (32%) and wheat (27%). Peanut (3.8%) and shellfish (3.5%) allergies were resolved far less frequently, consistent with the more persistent natural history typically observed for these allergens relative to milk, egg, soy, and wheat.¹

Racial and Socioeconomic Predictors of Resolution

White children reported resolution of food allergy more frequently than Black and Hispanic children across all common food allergens evaluated in the cohort.¹ This pattern held in unadjusted comparisons and persisted after investigators accounted for clinical and demographic covariates in multivariable models.

Lower family income, lower parental health literacy scores, and higher ADI, a composite measure of neighborhood-level socioeconomic disadvantage, were each observed more frequently among children who did not report resolution across all 9 common food and food groups assessed in the study.¹ Because FORWARD is observational and relies on caregiver-reported resolution rather than oral food challenge confirmation in all cases, the findings describe association rather than a mechanism, but the consistency across income, literacy, and geographic deprivation measures points to social determinants of health as a recurring factor in unequal food allergy outcomes.

An earlier analysis from the same research group, presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2024 annual meeting in a smaller cohort of 752 children, similarly found white children reported resolution of food allergy more often than Black or Hispanic children and linked higher household income to a greater likelihood of resolution.

 Investigators also reported that allergic rhinitis was associated with outgrowing food allergies (

The newly published FORWARD analysis extends those findings with a larger enrolled cohort and adds parental health literacy and ADI as independent predictors.

Dileep A, Bilaver LA, Warren C, et al. Factors Associated with Outgrowing Food Allergies: Insights from a Large Food Allergy Cohort. 

Facts and Statistics. Food Allergy Research & Education. Accessed August 17, 2026. 

https://www.foodallergy.org/resources/facts-and-statistics

Can My Child Outgrow a Food Allergy? What Parents Need to Know Today. University of Rochester Medicine. December 19, 2025. Accessed August 17, 2026. 

https://www.urmc.rochester.edu/news/publications/health-matters/can-my-child-outgrow-a-food-allergy

Abellard A, Alabduljabbar S, Bilaver L, et al. Sociodemographic Factors Associated with Outgrowing Food Allergy in Children. The Journal of Allergy and Clinical Immunology. Published February 2024. 

https://www.jacionline.org/article/S0091-6749(23)01660-3/fulltext

Caregiver-reported resolution of pediatric IgE-mediated food allergy in a large FORWARD cohort was unevenly distributed across allergens and sociodemographic strata. Resolution was most common for milk, soy, and wheat, while peanut and shellfish rarely resolved. White children more frequently reported resolution than Black and Hispanic children, including after multivariable adjustment. Lower household income, lower parental health literacy, and higher neighborhood deprivation (ADI) clustered among children without reported resolution, reinforcing social determinants as consistent correlates of disparate food allergy trajectories.

A FORWARD cohort study of 1,359 children found race, income, health literacy, and neighborhood deprivation each predicted food allergy resolution.

Race, Income, and Health Literacy Tied to Food Allergy Resolution

This week's highlight includes phase 3 trial results across dermatology, cardiology, and pulmonology, and a major conference preview.

Neurology

Neurology condition center page is a comprehensive resource for clinical news and insights on nervous system disorders. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for Alzheimer's disease, brain injury, PTSD, and more.

The HCPFive: Top News for Healthcare Providers from the Week of 08/09

Raj Chovatiya, MD, PhD, discusses why 2-year BE HEARD EXT data support earlier systemic therapy discussions and where unmet needs remain for HS.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Q&A: Rethinking Early Systemic Therapy for Hidradenitis Suppurativa

Mohamad Hussain, MD, PhD, a vascular and endovascular surgeon-scientist at the Heart and Vascular Institute, Mass General Brigham, and associate professor of surgery at Harvard Medical School

Mohamad Hussain, MD, PhD, discusses Phase 3 findings on Humacyte's bioengineered vessel and its potential role in vascular access for women on dialysis.

Chronic Kidney Disease

Bioengineered Vessel Increases Catheter-Free Time in Women on Dialysis

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

The FDA approved a single-use autoinjector for lerodalcibep-liga alongside an updated lerodalcibep-liga indication reflecting MACE risk reduction from LDL-C lowering with statins or add-on PCSK9 inhibitors.

Lipid Management

Lipid Management condition center page, resources on the topics of medical news and expert insight into lipidology can be found. Content includes articles, interviews, videos, podcasts, and breaking news on dyslipidemia research, treatment, and drug development.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Dyslipidemia

Lerodalcibep Autoinjector Receives FDA Approval for Hypercholesterolemia

Saakshi Khattri, MD, is a board certified Dermatologist, Rheumatologist and Internist and one of only a handful of triple board-certified physicians across the US.

In "BE BOLD Head-to-Head: IL-17 vs IL-23 for Psoriasis and PsA," the panel digs into the trial that broke the usual non-inferiority pattern.

Video Series

BE BOLD Head-to-Head: IL-17 vs IL-23 for Psoriasis and PsA

"Exploring the IL-17 vs IL-23 Debate in Psoriasis " takes up a deliberately provocative question from the moderator.

Exploring the IL-17 vs IL-23 Debate in Psoriasis

Pooled 2-year BE HEARD EXT data show shorter disease duration was linked with higher stringent response rates to bimekizumab in HS.

Q&A: Bimekizumab 2-Year Efficacy by HS Disease Duration, With Raj Chovatiya, MD, PhD

Raj Chovatiya, MD, PhD, discusses why bimekizumab response durability in HS held steady regardless of disease duration, and what it means for care.

Bimekizumab Data Support Case for Earlier Intervention in HS

Karen Alexander, MD, is a professor of medicine at Duke University Medical Center.

Karen Alexander, MD, discusses the recent statement evaluating the interconnected relationship between biological aging and cardiovascular risk.

ACC Statement Examines Frailty, Cognitive Impairment, in Cardiovascular Disease

Dana Rizk, MD, joins hosts Brendon Neuen and Shikha Wadhwani to unpack 2-year VISIONARY data showing sibeprenlimab stabilizes eGFR in IgAN.

Kidney Compass: Navigating Clinical Trials

Hosted by Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, Kidney Compass: Navigating Clinical Trials is a regular podcast exploring and breaking down the latest updates and nuances of clinical trials in nephrology. By listening to Kidney Compass, you'll get the guidance you need to navigate the changing landscape of clinical trials across the spectrum of kidney disease. 

Latest News

WAO Delphi Consensus Endorses ED05-Based Allergen Labelling

Investigational Rapid-Acting U500 Insulin Maintains Efficacy Regardless of BMI

Skin of Color Savvy: Mentorship in Dermatology—Building the Next Generation of Leaders

Understanding the B-Cell Pathway in IgA Nephropathy, With Samir Parikh, MD

Race, Income, and Health Literacy Tied to Food Allergy Resolution